Press Releases

03.24.2020

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis

03.18.2020

Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older

03.18.2020

 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

03.18.2020

Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns

03.18.2020

Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

03.17.2020

Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts

03.17.2020

Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine

03.17.2020

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

03.13.2020

Pfizer Outlines Five-Point Plan to Battle COVID-19

03.13.2020

EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study

03.04.2020

Susan Hockfield Elected to Pfizer’s Board of Directors

03.02.2020

U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis